AbbVie Secures Full FDA Approval for ADC Elahere in Ovarian Cancer 3/25/2024
Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion 3/25/2024
Wegovy Cardiovascular Approval Furthers March into New Indications 3/25/2024
Epigenetic Editing Explodes on the Heels of Gene Editing Success 3/25/2024
Merck, Others Look to Immunotherapy Combos as Next Frontier in Oncology 3/25/2024
Opinion: ALS Is Not a Singular Disease. Stop Treating It Like One 3/25/2024
Some anti-cancer treatments not only target tumour cells but also healthy cells. If their effects on the latter are too strong, their use can become limiting. A team from the University of Geneva (UNIGE), in collaboration with Basel-based FoRx Therapeutics, has identified the mechanism of action of PARP inhibitors, used in particular for breast and ovarian cancer in patients carrying the BRCA gene mutation.
FDA Approves Third Duchenne Muscular Dystrophy Treatment in Nine Months 3/22/2024
Medicare to Cover Novo’s Weight-Loss Drug Wegovy for Patients with Heart Disease 3/22/2024
Eledon’s Antibody Aids First Gene-Edited, Pig-to-Human Kidney Transplant 3/22/2024
Roche’s IL-6 Blocker Clears Phase III Bar, Still Falls Short of Expectations 3/22/2024
The Time Has Come to Make Weight-Loss Drugs Available to Those Who Need Them 3/22/2024
Bayer’s Prostate Cancer Drug Nubeqa on Track to Generate Blockbuster Sales in 2024 3/22/2024
An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit in a clinical trial led by the National Institutes of Health (NIH). Currently, there is no treatment for GAN and the disease is usually fatal by 30 years of age. Fourteen children with GAN, ages 6 to 14 years, were treated with gene transfer therapy at the NIH Clinical Center and then followed for about six years to assess safety.
Merck’s Keytruda Continues NSCLC Losing Streak with Phase III Flop 3/21/2024
Mirador Launches with $400M in Funding, Targets Precision Medicines 3/21/2024
Medicare Likely to Negotiate Prices for Obesity Drugs in Next Few Years: CBO 3/21/2024
Money Talk: Salary Trends and Raises 3/21/2024
Bayer Eliminates Nearly Half of Its Executive Positions in Major Overhaul 3/21/2024
Idorsia Wins FDA Approval in Hypertension Months After J&J Returned Rights to Drug 3/21/2024